Abstract: A microfluidic system comprising a plurality of photochemical reaction stages, the microfluidic system comprising a computational processor, a plurality of electrically-controllable photochemical reaction stages, and a series of controllable interconnections for connecting the photochemical reaction stages. In an implementation, the computational processor controls the electrically-controllable photochemical and other chemical reaction stages together with controllable interconnections so as to implement multi-step chemical processes. The microfluidic system can be configured to selectively drive a plurality of photochemical reactions within a mixture of chemical compounds via controlled emission of light of a plurality of wavelengths. The microfluidic system can be configured to comprise various interconnections and combinations of parallel and series chemical reaction stages, and can include a multichannel microfluidic chemical transfer bus.

Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.

Abstract: Embodiments of the present invention provide methods, microfluidic devices, and systems for the detection of an active target agent in a fluid sample. A substrate molecule is used that contains a sequence which may cleave in the presence of an active target agent. A SNAP25 sequence is described, for example, that may be cleaved in the presence of Botulinum Neurotoxin. The substrate molecule includes a reporter moiety. The substrate molecule is exposed to the sample, and resulting reaction products separated using electrophoretic separation. The elution time of the reporter moiety may be utilized to identify the presence or absence of the active target agent.

Abstract: This invention relates to a testing system arrangement for assessing the level of a biochemical marker, comprising a disposable device (2) with a sample inlet (4) and a at least one visible detection compartment (5A, 5B), for detection of said bio-chemical marker, a mobile unit (8) including a digital camera arranged to capture a digital picture (60) of said at least one visible detection compartment (5A, 5B), software run on a processor for analysing said picture (60) to assess said level and means arranged to present the result (70) of said assessment in a display (8A) of or connected to, said mobile unit (8), wherein said disposable device (2) is arranged with at least one reference surface (12) having a predetermined colour setting that is known to said software to enable exact assessment of the colour within said detection compartment (5A, 5B) by the use of said reference surface (12) within said digital picture as a basis reference.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.

Abstract: A sterilization indicator system and method of using the system to determine efficacy of a sterilization process. The system includes a vial having a first compartment containing spores of one or more species of microorganism; a second compartment containing a growth medium with a disaccharide, an oligosaccharide or a polysaccharide in which the vial is free of monosaccharide; an enzyme, capable of acting upon the monosaccharide to yield reaction products and electron transfer, disposed on two or more electrodes adapted to carry an electrical signal resulting from the electron transfer, the pair of electrodes positioned to contact the combined contents of the first compartment and the second compartment during incubation; and an apparatus linked or linkable to the electrodes and adapted to detect and measure the electrical signal resulting from electron transfer when the enzyme acts upon the monosaccharide.

Abstract: A biosensor comprising an electrically conductive substrate coated with a modified chitosan biopolymer that has been electrodeposited on the substrate, wherein said modified chitosan biopolymer comprises at least one vesicle binding molecule. The biosensor is manufactured by a method where a modified chitosan biopolymer is electrodeposited on a substrate. The method is also used to manufacture a modified chitosan biopolymer film by electrodeposition of the chitosan on the substrate and later removing the film from the substrate after electrodeposition. The resulting film can be used in bandages to treat various types of wounds. The biosensor can also be used to detect various analytes in samples.

Abstract: The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. In particular, the methods include a [3+2] cycloaddition between a nucleotide analog incorporated into a nucleic acid polymer and a reagent attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures.

Abstract: A sensor chip is configured to measure the temperature of a blood sample and includes a capillary section and an electrode unit. The capillary section allows the blood sample to be introduced therein. The electrode unit is configured to measure the temperature of the blood sample and includes a working electrode and a counter electrode. The working electrode and the counter electrode respectively include a reaction reagent layer containing an electrolyte. Further, the electrode unit is configured to receive a predetermined voltage to be applied in measuring the temperature of the blood sample for allowing a result of the measurement to be less affected by increase and reduction in a glucose concentration and the like.

Abstract: The present application relates to a sensor (1) for use in detecting an analyte comprising: a transducer (10) composed of a pyroelectric or piezoelectric polymer substrate e.g. PVDF (3) and a transparent electrode layer (4) on a surface of the substrate; a layer of parylene (12) on the transparent electrode layer; and a reagent (17) immobilised on the transducer, the reagent having a binding site which is capable of binding the analyte or a derivative of the analyte.

Abstract: The measurement device comprises a sensor holder to which is removable to a biosensor. The sensor holder has measurement-use connection terminals that are in contact with the electrode system in the biosensor and are used to take off signals required for measuring the specific component, and thermocouple-use connection terminals that are in contact with the thermocouple in the biosensor and are used to take off the thermoelectromotive force signals.

Abstract: The present invention relates to a device for visual detection of hemolysis in a whole blood sample, comprising at least one visible detection compartment and a transfer passage connected to said visible detection compartment, said transfer passage being arranged to permit transfer of a volume of plasma from said sample to said detection compartment and wherein said transfer passage further is arranged with a separation device (4) for separating plasma from blood cells within said whole blood sample before said plasma reaches the detection compartment, wherein said device is arranged with subpressure means providing a subpressure inside said detection compartment for generating a force urging said volume of plasma to be transferred from said whole blood sample to said detection compartment through said transfer passage and via said separation device.

Abstract: A cholesterol-level measuring apparatus including a portable body having a cholesterol level detecting means for identifying a cholesterol level in a blood sample, and a display screen communicatively coupled to the cholesterol level detecting means for illustrating a learned cholesterol level in the blood sample. Notably, the cholesterol level detecting means includes a disposable test strip having a color-changing reactive reagent that changes color in response to the learned cholesterol level in the blood sample.

Abstract: An endometriosis diagnostic in which a biological sample of a female mammal having had a menstrual cycle within 90 days of the biological sample having been obtained from the female mammal is subjected to an in vitro diagnostic procedure in which the biological sample is contacted with an apatite compound for an effective time to provide a responsive visual appearance. Based on the visual appearance, a determination is made whether the female mammal has endometriosis.

Abstract: A biosensor system determines analyte concentration from an output signal generated by an oxidation/reduction reaction of the analyte. The biosensor system adjusts a correlation for determining analyte concentrations from output signals at one temperature to determining analyte concentrations from output signals at other temperatures. The temperature-adjusted correlation between analyte concentrations and output signals at a reference temperature may be used to determine analyte concentrations from output signals at a sample temperature.

Abstract: The invention provides a method of monitoring the response of platelets to a cyclooxygenase-1 (COX1) inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX1 inhibitor; mixing the blood with a COX1-dependent platelet agonist, such as arachidonic acid, monitoring extracellular ATP in the agonist-activated blood to generate a measurement, and comparing the measurement to a standard value. Devices, systems, and kits for carrying out the method are also provided.

Abstract: A method is disclosed for measuring the properties of protein and lipoprotein elements in a sample.

Abstract: Devices and methods for measuring prothrombin time (PT) and hematocrit (HCT) by analyzing the change in reactance in a sample are presented. A diagnostic device for measuring HCT and PT of a fluid includes a relative electrode-type sensor device and a blood test card assembly including one or more pairs of electrodes, wherein alternating current (AC) provided by the sensor device is used to measure and calculate HCT and PT of blood test using the reactance analysis.

Abstract: An isolated antibody that has a specific binding affinity to a polypeptide comprising the amino acid sequence HTEGKP (SEQ ID NO: 2) phosphorylated at threonine is provided. The antibody may be used as biomarker for mitotic cells. A method for using the antibody in accordance with the invention comprises contacting a cell with the antibody and detecting antibody bound to the cell as an indicator of the cell being in the mitotic state. A reagent kit comprising the antibody is also provided.

Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.

Abstract: Provided are methods for determining and analyzing photometric and morphometric features of small objects, such as cells to, for example, identify different cell states. In particularly, methods are provided for identifying apoptotic cells, and for distinguishing between cells undergoing apoptosis versus necrosis.

Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.

Abstract: A microfiltration apparatus and method for separating cells, such as circulating tumor cells, from a sample using a microfiltration device having a top porous membrane and a bottom porous membrane. The porous membranes are formed from parylene and assembled using microfabrication techniques. The porous membranes are arranged so that the pores in the top membrane are offset from the pores in the bottom membrane.

Abstract: The present invention discloses certain genetic variants as susceptibility variants for peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA). The invention relates to risk management using such variants. The invention further relates to kits for use in risk assessment of PAD and AAA.

Abstract: Fluidic connectors, methods, and devices for performing analyses (e.g., immunoassays) in microfluidic systems are provided. In some embodiments, a fluidic connector having a fluid path is used to connect two independent channels formed in a substrate so as to allow fluid communication between the two independent channels. One or both of the independent channels may be pre-filled with reagents (e.g., antibody solutions, washing buffers and amplification reagents), which can be used to perform the analysis. These reagents may be stored in the channels of the substrate for long periods amounts of time (e.g., 1 year) prior to use.

Abstract: The apparatus and method for detecting blood in urine or feces includes a photodetector configured to detect a transient light emitted in a toilet bowl by luminol and an oxidizer catalyzed by iron in the blood. The apparatus may include dispensers for the luminol, the oxidizer and a base. The apparatus may include a microprocessor and a network connection and may perform statistical analyzes, store data and alert the patient or a healthcare provider if blood is detected. The photodetector may be configured to detect light emitted in the toilet bowl by a fluorophore present in the water and excited by the transient light from the luminol and oxidizer.

Abstract: The invention identifies and describes proteins that are differentially expressed in platelets resistant to anti-platelet agents such as aspirin (acetylsalicyclic acid) compared to those platelets that are sensitive to such agents. Methods for determining further such differentially expressed proteins and methods for determining an individual's sensitivity to anti-platelet agents, such as aspirin, prior to administration.

Abstract: The invention relates to a method for treating a biological sample, comprising the following method steps: i) preparation of a biological sample and ii) bringing the biological sample into contact with a composition, comprising: (1) 1 to 100 wt. % of at least one polyol and (2) 0 to 99 wt. % of at least one additive, wherein the total amount of components (1) and (2) is 100 wt. %. The invention further relates to biological samples obtained by said method, a method for analysis of a treated biological sample, devices for treating a biological sample, use of said devices, various kits and use of a composition.

Abstract: A microchip for measuring platelet function by allowing blood to flow through a channel to induce platelet aggregation, wherein the microchip has a channel provided inside thereof, wherein at least a part of the channel is coated with collagen for allowing adhesion of platelets; a plurality of walls extend along the direction of the flow of blood in the channel and divide the width of the channel to form a channel dividing section; and the walls are treated to have a surface roughness (Ra) of 10 to 200 nm.

Abstract: A sample analyzer is disclosed. In one embodiment, the sample analyzer includes an analysis section for analyzing a sample by using a reagent to obtain numerical data and distribution diagram of particles contained in the sample; a display device; an information receiver for receiving an input of reagent information assigned to the reagent; a determination section configured for determining whether or not the reagent satisfies a condition to determine that the reagent is a genuine product based on the reagent information; and a controller that controls the display device to display both the numerical data and the distribution diagram if the reagent satisfies the condition by the determination section and to display the numerical data without displaying the distribution diagram if the reagent does not satisfy the condition by the determination section.

Abstract: The invention provides a reagent for diluting a blood sample, comprising water, polyoxyethylene alkyl ether having a hydroxyl value of 52 to 60, and an osmo-regulator for regulating the osmotic pressure of the reagent in the range of 150 to 400 mOsm/kg, as well as a method for measuring the mean corpuscular volume of a blood sample.

Abstract: The invention provides a method of assaying for tetrahydrocannabinol in a body fluid. The method includes contacting a sample of body fluid with an imine capable of reacting with tetrahydrocannabinol to yield a quinone imine, and detecting the formation of a quinone imine, where the sample is contacted with the reagent compound at a pH of at least 10.5.

Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

Abstract: The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety.

Abstract: Described herein are high-throughput methods of monitoring D-serine levels in plasma. The assay involves the use of strong cation solid phase extraction (SPE) to isolate D-serine from plasma, followed by quantitation of D-serine using the D-amino acid oxidase- (DAAO-) catalyzed reaction. Also described are methods of screening for compounds that act as DAAO inhibitors.

Abstract: A method and apparatus for determining the hematocrit of a blood sample disposed within an analysis chamber, the method including the steps of: a) imaging at least a portion of the sample that contains one or more red blood cells and one or more areas void of red blood cells; b) determining a representative optical density value for a plurality of image units optically aligned with portions of the red blood cells, and assigning an optical density first boundary value to those image units; c) determining a representative optical density value of a plurality of image units optically aligned with the one or more regions of the sample devoid of red blood cells, and assigning a second optical density boundary value to those image units; and d) determining the hematocrit of the sample.

Abstract: The at home cancer test permits a layperson to qualitatively test for the presence of carcinoma in the privacy of their home. The test includes a test strip coated or impregnated with at least one monoclonal antibody that binds to ?-hCG/CGH found in the patient's urine, together with a chromophore that provides a color indicator when such binding takes place. The at-home cancer test may comprise a kit containing one or more of the following: a test strip with a tab that can be gripped by the user while the strip is placed in a stream of urine; a cup for collecting urine and a test strip that may be partially immersed in the cup; and a cup for collecting urine, a test strip, and a medicine dropper or pipette for transferring the urine to the test strip.

Abstract: An apparatus and method for platelet multi-function analysis using measurement of electrical characteristics, and a stirring microchip are provided. The apparatus for platelet multi-function analysis includes a stirring microchip that has a sample storage chamber formed therein to hold a blood sample, and in which an inner part of the sample storage chamber is coated with reagents composed of collagen and epinephrine, or collagen and ADP. The apparatus for platelet multi-function analysis further includes a microstirrer installed inside the stirring microchip to stir the blood sample and the reagents in the stirring microchip and a stirring induction unit configured to facilitate stirring of the microstirrer. Therefore, the platelet aggregation and multi-function analysis can be performed using a trace of blood, and the platelet aggregation and multi-function analysis can also be performed using the whole blood taken from the veins through a vacuum tube containing an anticoagulant.

Abstract: The present invention provides simple and rapid methods for measuring the function of a desired subset of lymphocytes, for example, T cells, B cells or NK cells. In addition, the present invention provides an all-in-one kit that contains reagents which permit a rapid and reliable analysis of the functions of T cells, B cells and NK cells obtained directly from whole blood or cord blood.

Abstract: A method of differentiating among the presence of ductal carcinoma in situ in the breast, benign fibroadenoma of the breast, and non-cancerous breast tissue in a subject is disclosed. The method involves measuring the concentration of at least one protein biomarker selected from a group of forty-nine differentially expressed proteins in the saliva of persons with DCIS, or benign fibroadenoma, or in persons who are cancer-free. The resulting test data is compared to a reference panel. From the comparison the presence in the subject of either ductal carcinoma in situ of the breast, or benign fibroadenoma of the breast is determined.

Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells.

Abstract: Device, method, and computer program product for determining a material parameter of a blood coagulation cascade based on parameters of light diffused at a biofluid sample. In one example, the biofluid sample includes a blood sample. Laser light scattered by the sample is collected by the optical system in reflection and/or transmission mode. An image of the sample in so collected light is formed, and data representing fluctuations of laser speckle intensity with is processed to derive numerical descriptors associated with blood coagulation and fibrinolysis. In a specific case, such numerical descriptors are derived based on temporal dynamic of a viscoelastic characteristic of the blood sample.

Abstract: The present disclosure provides methods to predict the risk of CHD and/or clinical manifestations of CHD in a subject. In one embodiment, the method involves measuring the levels or concentration of apo A1, a subclass of HDL, HDL3, or a combination of the foregoing. The methods of the present disclosure are particularly useful when the subject has reached target levels of one or more lipoproteins, such as, but not limited to, LDL or HDL or subclass of the foregoing.

Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.

Abstract: The present disclosure provides isotopically substituted compounds of the formula (II): wherein T, U, V, W, X, Y, Z, R0, R3, R4, R5 and R6 are as defined in the detailed description. The method for detection and quantification using the same is also disclosed.

Abstract: The invention relates to microscale cell separating apparatus which are able to separate cells on the basis of size of the cells, interaction of the cells with surfaces of the apparatus, or both. The apparatus comprises a stepped or sloped separation element (16) interposed between an inlet region (20) and an outlet region (22) of a void that can be tilled with fluid. The void can be enclosed within a cover (12) and fluid flow through the void engages cells with the separation element. Only cells which have (or can deform to have) a characteristic dimension smaller than or equal to the distance between a step and the cover or body can pass onto or past a step. Modifications of surfaces within the apparatus can also inhibit passage of cells onto or past a step.

Abstract: In order to provide a reagent kit for detecting LA which can clearly separate a lupus anticoagulant (LA)-positive specimen group from an LA-negative specimen group, it is configured that the reagent kit for detecting LA contains a first clotting time-measuring reagent and a second clotting time-measuring reagent and at least one of the first clotting time-measuring reagent and the second clotting time-measuring reagent contains alkali metal salt. The presence or absence of LA can be determined using the kit.

Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

Abstract: The present invention provides a method of pretreating a sample containing a glycated amine as an analyte, thereby enabling highly reliable measurement of a glycated amine. A glycated amino acid in the sample is degraded by causing a fructosyl amino acid oxidase (FAOD) to act thereon, and thereafter, a FAOD further is caused to act on the glycated amine as the analyte in the sample to cause a redox reaction. The amount of the glycated amine is determined by measuring the redox reaction. The substrate specificity of the FAOD caused to act on the glycated amino acid may be either the same as or different from that of the FAOD caused to act on the glycated amine. When using the same FAOD, a FAOD is caused to act on the glycated amino acid to degrade it, and thereafter, the sample is treated with a protease to inactivate the FAOD and also to degrade the glycated amine.